Bejel is an infectious rare disease that belongs to spirochete treponema pallidum bacterium family. The organisms cause ulceration (lesions) on mucous membrane (skin), particularly in or near mouth. Also, these organisms progress gradually appear on arms, legs and bones that convert Bejel to most severe stages. Bejel treatment has other symptoms such as lymph nodes or swollen glands, groin and skin ulceration around the rectum. The transmission of these infections is by means skin contact and through common use of drinking & eating utensils. Bejel infection is familiar to syphilis but it is not transmitted sexually. Other related disorders that can be similar to bejel treatment symptoms are Pinta, Yams and Syphilis.
Rising population coupled with emerging prevalence of infectious disease in developing countries may trigger the bejel treatment market during the coming years. The bejel treatment market is attributed to increasing incidence rate of pathogen that are serologically and morphologically indistinguishable. Furthermore, availability of favorable reimbursement policies and various programs initiated by government and non-government bodies for bejel treatment market in developed and under developing economies will propel the bejel treatment market expansion. However, Lack of manufacturers of benzathine penicillin G and healthcare infrastructure may deter the growth of bejel treatment market.
The global Bejel treatment market is segmented on the basis of drug type, transmission type, route of administration, end user and geography:
Increasing prevalence of infectious disease and high life expectancy worldwide may drive the bejel treatment market. The bejel treatment market is expected to witness tremendous growth owing to rising incidence rate of change to sedentary lifestyle, unhygienic conditions and population base amongst others. Disease is transmitted through sexual transmission men having sex with men (MSM), skin-to-skin contact and common use of eating and drinking utensils, leading to infectious disease that will boost the bejel treatment market growth. For instance, according to Centers of Disease Control and Prevention (CDC) report, in Japan, approximately 5 patients were suffering from bejel disease caused by MSM (Men having sex with Men) transmission. Additionally, various programs and initiatives by organizations and government regarding awareness on hygiene conditions and hospital settings are boosting the market progress.
North America will show lucrative revenue for the bejel treatment market owing to increasing incidence of skin infections. After North America, the Europe region will show the robust growth for the bejel treatment market in the near future, due to availability of higher hospital facilities and growing healthcare infrastructure in European unions. Latin America region will show the significant demand for the bejel treatment, due to the regional government initiative towards pathogenic infections in countries like Brazil and Mexico. In Asian countries like China and India, the rate of life expectancy, increasing population base and unhygienic conditions thereby may show the additional demand for the bejel treatment market expansion. The Middle East and Africa are expected to be least lucrative region for bejel treatment market due to lack of awareness regarding hygienic conditions, healthcare setting and climatic conditions.
Examples of some of the market participants in bejel treatment market identified across the value chain include Pfizer Inc, APP Pharmaceuticals, Abcam plc., Baxter International Inc., C.O. Truxton Inc., King Pharmaceuticals Inc., Physicians Total Care Inc., Alembic IT Department, ECPlaza Network Inc, Sandoz International GmbH, Triveni Interchem Private Limited, CSPC Pharmaceuticals Group Ltd, Semisyntech Co. Ltd, CSC Pharmaceuticals International,Merck KGaA, and others.
The report covers exhaustive analysis on:
Regional analysis includes